RecruitingNot Applicable

The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp

Denmark60 participantsStarted 2020-04-15

Plain-language summary

The aim of the study is to 1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how. 2. To determine whether salicylate treatment changes the effect of EPO (erythropoietin) on platelet function.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Known allergy to ASA
✕. Known contraindication to ASA, e.g. recent bleeding episode.
✕. Known indication for ASA. If the patient is being treated with ASA, and the physician does not find any indication for this treatment, this can be stopped, and the patient included after 4 weeks.
✕. Raised reticulocyte count
✕. Current anticoagulant therapy, e.g. warfarin, ADP receptor inhibitor (excepting short-term anticoagulant therapy in connection with dialysis)
✕. Short expected length of life
✕. Inability to give informed consent
✕. Expected non-compliance

What they're measuring

Thrombocytaggregometry

Timeframe: 16 weeks

Trial details

NCT IDNCT04330729

SponsorZealand University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Mette KOefoed, md

0045 93576330 mkof@regionsjaelland.dk

View on ClinicalTrials.gov More Erythropoietin Adverse Reaction trials